Evidence map›Paper›PMID 29467555›Full record

ArticleWorld journal of gastroenterology2018

Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.

Niels Steinebrunner, Kerstin Stein, Catharina Sandig, Thomas Bruckner, Wolfgang Stremmel, Anita Pathil

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Niels SteinebrunnerDepartment of Internal Medicine IV, University Hospital Heidelberg, Heidelberg 69120, Germany.
Kerstin SteinDepartment of Gastroenterology, Hepatology and Infectious Diseases, University Hospital of Magdeburg, Magdeburg 39120, Germany.
Catharina SandigDepartment of Internal Medicine IV, University Hospital Heidelberg, Heidelberg 69120, Germany.
Thomas BrucknerDepartment of Medical Biometry, Institute of Medical Biometry and Informatics (IMBI), Heidelberg 69120, Germany.
Wolfgang StremmelDepartment of Internal Medicine IV, University Hospital Heidelberg, Heidelberg 69120, Germany.
Anita PathilDepartment of Internal Medicine IV, University Hospital Heidelberg, Heidelberg 69120, Germany. anita.pathil-warth@med.uni-heidelberg.de.
Heidelberg University · DEUniversity Hospital Magdeburg · DEZimmer Biomet (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo define predictors of functional benefit of direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) infection and liver cirrhosis.

methodsWe analysed a cohort of 199 patients with chronic HCV genotype 1, 2, 3 and 4 infection involving previously treated and untreated patients with compensated (76%) and decompensated (24%) liver cirrhosis at two tertiary centres in Germany. Patients were included with treatment initiation between February 2014 and August 2016. All patients received a combination regimen of one or more DAAs for either 12 or 24 wk. Predictors of functional benefit were assessed in a univariable as well as multivariable model by binary logistic regression analysis.

resultsViral clearance was achieved in 88% (175/199) of patients. Sustained virological response (SVR) 12 rates were as follows: among 156 patients with genotype 1 infection the SVR 12 rate was 90% (

conclusionOur data may contribute to the discussion of potential risks and benefits of antiviral therapy with individual patients infected with HCV and with advanced liver disease.

Indexed as

AdultAgedAged, 80 and overAntiviral AgentsDrug Therapy, CombinationEnd Stage Liver DiseaseFemaleFollow-Up StudiesGermanyHepacivirusHepatitis C, ChronicHumansLiver CirrhosisLiver Function TestsLongitudinal StudiesMaleAntiviral AgentsCirrhosisDirect acting antiviralFunctional benefitHepatitis CReal-life data

Identifiers

PMID29467555
PMCPMC5807943
OpenAlexW2785620293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.